There are four vaccines that are in phase 3 clinical trials in the USA. They are
* BioNTech/Pfizer vaccines
* Johnson & Johnson viral vector vaccine.
* Oxford/AstraZeneca viral vector vaccine
A fifth vaccine should start US trials in October.
The two current leaders are Pfizer and Moderna.
The CEO of Pfizer said on the Today Show that the results of their phase 3 clinical trial for a coronavirus vaccine could be ready by the end of October. If there was a positive result, Pfizer would be ready to apply immediately for an emergency FDA approval for medical workers and at-risk individuals. BioNTech is Pfizer’s partner fo the vaccine. BioNTech is planning to buy a Novartis certified vaccine production facility in Germany. This would increase COVID-19 vaccine production capacity by up to 750 million doses per year. 44,000 people are now being tested in the vaccine trial.
The CEO of Moderna told the Financial Times that they would not be ready to get Food and Drug Administration approval for the general population until at least late January 2021. The approval would not be made until late March or early April. Moderna won’t seek emergency authorization for their vaccine until November 25, 2020.
AstraZeneca plc’s vaccine is in late-stage trials in the U.K., India and South Africa. The phase 3 clinical trial in the USA is still halted as they investigate someone who died in the trial.
Johnson & Johnson started their vaccine in phase 3 trials on September 23. They are targeting early 2021 for an emergency application.
Novavax has Phase 3 study of its NVX-CoV2373, a recombinant nanoparticle vaccine, in the U.K. They should late-stage study in the U.S. in October.
SOURCES- Today, Bezinga, Financial Times, FDA, Pfizer, Moderna
Written by Brian Wang, Nextbigfuture.com
Brian Wang is a Futurist Thought Leader and a popular Science blogger with 1 million readers per month. His blog Nextbigfuture.com is ranked #1 Science News Blog. It covers many disruptive technology and trends including Space, Robotics, Artificial Intelligence, Medicine, Anti-aging Biotechnology, and Nanotechnology.
Known for identifying cutting edge technologies, he is currently a Co-Founder of a startup and fundraiser for high potential early-stage companies. He is the Head of Research for Allocations for deep technology investments and an Angel Investor at Space Angels.
A frequent speaker at corporations, he has been a TEDx speaker, a Singularity University speaker and guest at numerous interviews for radio and podcasts. He is open to public speaking and advising engagements.